Renoprotective Effects of Mineralocorticoid Receptor Antagonists Against Diabetic Kidney Disease

Diabetic kidney disease (DKD) is a growing epidemic worldwide and a leading cause of end‐stage kidney disease. Mineralocorticoid receptor (MR) blockade using Finerenone is a recently approved therapeutic approach to slow down the progression of DKD in patients with type 2 diabetes in addition to oth...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Advanced biology 2024-03, Vol.8 (3), p.e2300496-n/a
Hauptverfasser:	Bayne, Sarah, LeFevre, James, Olstinske, Kayla, Ravindran, Sreenithya, Munusamy, Shankar
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiotensin Receptor Antagonists - pharmacology Angiotensin Receptor Antagonists - therapeutic use Angiotensin-Converting Enzyme Inhibitors - pharmacology Angiotensin-Converting Enzyme Inhibitors - therapeutic use Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetic Nephropathies - drug therapy Diabetic Nephropathies - etiology Diabetic Nephropathies - prevention & control diabetic nephropathy eplerenone fibrosis finerenone Humans inflammation mineralocorticoid receptor antagonists Mineralocorticoid Receptor Antagonists - pharmacology Mineralocorticoid Receptor Antagonists - therapeutic use renin‐angiotensin‐aldosterone system
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!